PYPD
PolyPid Ltd.
stockNASDAQ

PYPD. They're already preparing for commercialization and have multiple studies now that confirm their product is safe and effective. It's local to site so their is no systemic effects on the body.

$CAPR — Nov 22 | Duchenne muscular dystrophy $SVRA — Nov 22 | Rare lung disease $COGT — Nov 30 | Cancer treatment $BTAI — Nov 14 | Bipolar agitation treatment $PYPD — Nov 28 | Surgical infection prevention FDA decisions can trigger major price swings in small cap biotech stocks. Watch for volume, momentum and official FDA updates.

I keep a log of the dates biotech companies give for FDA decisions, then record what actually happened. Last week had three: \- NRXP (KETAFREE, preservative-free ketamine, ANDA): company-stated GDUFA goal date Nov 10, 2026. Approved Oct 30, 11 days early. \- INO (INO-3107, now VOCERYQ, BLA): PDUFA target date Oct 30, 2026. Accelerated approval Oct 30, on the stated date. \- AGIO (mitapivat sNDA, sickle cell disease): goal date was Nov 1, 2026. The company says FDA classified its response as a major amendment; new goal date Feb 1, 2027. Sources: company press releases from Oct 30 (SEC filings still pending for some). Next company-stated FDA dates on my list: CYTK and SMMT Nov 14, SVRA and CAPR Nov 22, SNY Nov 25, PYPD Nov 28, CORT Dec 17. Not advice and no predictions, just what companies said vs. what happened. Happy to share the source for any line.